The company invested $80m in the new facility which encompasses a current Good Manufacturing Practice (cGMP) grade pilot plant and office space.
The 60,000ft² facility will begin production operations in late 2012 and GMP manufacturing in 2013. The company has also hired 23 new employees to work at the facility and expects additional jobs to be created in the near future.
Morphotek executive vice president and chief operating officer Philip Sass said with the opening of the new pilot plant the company will have the capability to produce therapeutic antibodies efficiently.
"The facility is designed and equipped to produce multiple biologics simultaneously and will enable us to initiate more Phase I studies to test the safety and efficacy of our lead antibodies than we could previously," Sass added.